Antigenic properties of the SARS-CoV-2 nucleoprotein are altered by the RNA admixture

View article
Biochemistry, Biophysics and Molecular Biology

Main article text

 

Introduction

Materials & Methods

Molecular cloning

Bacterial culture

NP and NTD purification

Nucleic acids concentration measurement

SDS-PAGE

Analytical size-exclusion chromatography

Dynamic light scattering (DLS)

Enzyme-linked immunosorbent assay (ELISA)

Mass spectrometry

Statistical analysis

Results

Expression and purification of the intact NP

Expression and purification of the NTD and CTD fragments

NP oligomerization state analysis

ELISA

Discussion

Conclusions

Supplemental Information

Supporting figures and supporting table

DOI: 10.7717/peerj.12751/supp-1

Aminoacid sequences of the nucleocapsid protein (NP) and it’s fragments, as encoded by the plasmids pHYP-NPC-10H, pHYP-NP-head-C-10H, pHYP-NP-tail-C-10H

Sequences are in FASTA format.

DOI: 10.7717/peerj.12751/supp-2

IMAC chromatography trace for the RNase A- treated NP sample, on-column wash by the stepwise NaCl concentration gradient

Eluate absorbance at 280 nm is in blue, absorbance at 260 nm –in red, conductivity in brown. Ten minutes of the flow stops were performed at the end of each NaCl gradient segment, resulting in appearance of peaks, preceding the eluate from the next segment.

DOI: 10.7717/peerj.12751/supp-3

Absence of the NP CTD expression in the BL21[DE3]/pHYP-NP-CTD strain

SDS-PAGE analysis of total E.coli proteins, 2 h induction by 1 mM IPTG, 30 oC, total proteins (induced), soluble and insoluble protein fractions. Cl.5, cl. 7–transformation of the BL21[DE3] cells by two various clones of the pHYP-NP-CTD plasmid.

DOI: 10.7717/peerj.12751/supp-4

Raw data of the ESI-MS analysis of the full-length NP preparation

DOI: 10.7717/peerj.12751/supp-5

Raw data of the ESI-MS analysis of the NTD preparation

DOI: 10.7717/peerj.12751/supp-6

Chromatography traces of the NP and NP-RNA protein preparations size exclusion chromatography analysis, dual wavelength optical detection

(A, B) PBS as the mobile phase; (C, D) 300 mM NaCl, 20 mM sodium phosphate pH 7.5, 100 mM imidazole-HCl mobile phase; (E, F) 2 M NaCl, 20 mM sodium phosphate pH 7.5, 100 mM imidazole as the mobile phase. (C, D) are same to the Figs. 2E 2F and are shown here for ease of the direct visual analysis.

DOI: 10.7717/peerj.12751/supp-7

Chromatography traces of the NP and NTD protein preparations size exclusion chromatography analysis, MALS and 280 nm detection

(A) NP; (B) NTD. Molar masses, determined by the MALS detector, are shown on left side of peaks, molecular masses, determined by the calibration curve interpolation, are shown above peaks.

DOI: 10.7717/peerj.12751/supp-8

Size distribution by dynamic light scattering for NP variants

(A, B) particle size distribution by intensity and volume for the pure NP antigen. (C, D) RNase A–treated NP, no 2 M NaCl wash. (E, F) Rnase A–untreated NP, with 2 M NaCl wash. (G, H) NP-RNA.

DOI: 10.7717/peerj.12751/supp-9

Size distribution by dynamic light scattering for NTD variants

(A, B) particle size distribution by intensity and volume for the pure NTD antigen. (C, D) RNase A–treated NTD, no 2 M NaCl wash. (E, F) Rnase A–untreated NTD, with 2 M NaCl wash. (G, H) NTD-RNA.

DOI: 10.7717/peerj.12751/supp-10

Chromatography traces of the NTD and NTD-RNA protein preparations size exclusion chromatography analysis, dual wavelength optical detection

(A, B) PBS as the mobile phase; (C, D) 300 mM NaCl, 20 mM sodium phosphate pH 7.5, 100 mM imidazole-HCl mobile phase; (E, F) - 2 M NaCl, 20 mM sodium phosphate pH 7.5, 100 mM imidazole as the mobile phase.

DOI: 10.7717/peerj.12751/supp-11

Antibody capture ELISA and dynamics of the assay specificity ratios for various purification methods, NP antigen

(A) pure NP antigen, protein preparation and the ELISA test was independent from the test shown on Fig. 3. (B) NP protein antigen, treated by the RNase A and not treated by the on-column 2 M NaCl wash. (C) NP protein antigen, not treated by the RNase A and treated by the on-column 2 M NaCl wash. (D) NP-RNA antigen, protein preparation and the ELISA test was independent from the test shown on Fig. 3. (E) negative control TrxA antigen, purified exactly as the NP antigen. (F) (OD+/OD-) for various serum samples dilutions, calculated as the ratios of OD readings for the PCR+ sample and the pre-COVID sample for the same sample dilutions. Blue lines - pooled PCR+ sera. Red lines - pooled pre-COVID sera. Statistical analysis by the or one-way ANOVA with the post-hoc Tukey-Kramer HSD test, n = 2, * - p < 0.05; ** - p < 0.01; *** - p < 0.001, ns–non-significant. P-values are presented for the pure NP antigen versus three other antigen preparations as “NP vs. NP+-; NP vs. NP-+; NP vs. NP-RNA”.

DOI: 10.7717/peerj.12751/supp-12

Antibody capture ELISA and dynamics of the assay specificity ratios for various purification methods, NTD antigen

(A) pure NTD antigen, protein preparation and the ELISA test was independent from the test shown on Fig. 3. (B) NTD protein antigen, treated by the RNase A and not treated by the on-column 2 M NaCl wash. (C) NTD protein antigen, not treated by the RNase A and treated by the on-column 2 M NaCl wash. (D) NTD-RNA antigen. (E) test specificity ratios (OD+/OD-) for various serum samples dilutions, calculated as the ratios of OD readings for the PCR+ sample and the pre-COVID sample at the same sample dilutions. Blue lines - pooled PCR+ sera. Red lines - pooled pre-COVID sera. Statistical analysis by the or one-way ANOVA with the post-hoc Tukey-Kramer HSD test, n = 2, * - p < 0.05; ** - p < 0.01; *** - p < 0.001, ns–non-significant. P-values are presented for the pure NP antigen versus three other antigen preparations as “NTD vs. NTD+-; NTD vs. NTD-+; NTD vs. NTD-RNA”.

DOI: 10.7717/peerj.12751/supp-13

Raw bitmap images

As acquired by the flatbed scanner or video camera.

DOI: 10.7717/peerj.12751/supp-14

Chromatography traces

Waters Empower output, converted to .xls

DOI: 10.7717/peerj.12751/supp-15

Primary ELISA OD readings, Student’s p- values. File names according to figure’s panels names.

DOI: 10.7717/peerj.12751/supp-16

Dataset used for calculations in Fig. 4

DOI: 10.7717/peerj.12751/supp-17

Additional Information and Declarations

Competing Interests

Ivan I. Vorobiev and Nadezhda A. Orlova are inventors of the patent RU2496877, covering the use of the pHYP plasmid.

Author Contributions

Denis E. Kolesov performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Maria V. Sinegubova performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Irina V. Safenkova conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.

Ivan I. Vorobiev conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Nadezhda A. Orlova conceived and designed the experiments, performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.

Patent Disclosures

The following patent dependencies were disclosed by the authors:

Patent RU2496877, PLASMID VECTOR pHYP WITH HIGH SEGREGATION STABILITY FOR EXPRESSION OF RECOMBINANT PROTEIN, BACTERIUM - PRODUCENT OF PRECURSOR OF RECOMBINANT PROTEIN AND METHOD TO PRODUCE RECOMBINANT PROTEIN, priority date 2011-12-15

Data Availability

The following information was supplied regarding data availability:

The zip-compressed bitmap images, as acquired by the scanner and camera; archived ELISA readings; archived chromatography traces are available in the Supplementary Files.

The code is available at GitHub: https://github.com/d-kolesiko/ELISA.

Funding

The study was supported by the Russian Foundation for Basic Research (grant 20-58-55001) and the Ministry of Science and Higher Education of the Russian Federation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

4 Citations 2,239 Views 142 Downloads

Your institution may have Open Access funds available for qualifying authors. See if you qualify

Publish for free

Comment on Articles or Preprints and we'll waive your author fee
Learn more

Five new journals in Chemistry

Free to publish • Peer-reviewed • From PeerJ
Find out more